Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib plus radiotherapy versus concurrent chemoradiotherapy in unresectable EGFR-mutated stage III NSCLC
ChiCTR2000040590Phase 3Not yet recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of almonertinib, cisplatin and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
almonertinibcisplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000040590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040590.